Brought to you by 
ApolloBio gets non-oncology rights to Inovio's pre-cancer immunotherapy; deal terms later amended
16 Nov 2021
Executive Summary
Inovio Pharmaceuticals Inc. granted ApolloBio Corp. exclusive rights to develop and sell its DNA immunotherapy VGX3100 in Greater China (China, Hong Kong, Macau, and Taiwan). The deal could be expanded to include Korea in three years.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ApolloBio gets non-oncology rights to Inovio's pre-cancer immunotherapy; deal terms later amended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice